Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 20/20 | 0.40 |
| ▸ | PDE4A | P27815 | 11/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680467 | 0.95 | PDE4D (0.37) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3676661 | 0.95 | PDE4D (0.37) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL917973 | 0.92 | PDE4D (0.41) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL916251 | 0.92 | PDE4D (0.39) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL917619 | 0.92 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL918227 | 0.91 | MEN1 (0.39) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL916825 | 0.90 | PDE4D (0.41) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL918339 | 0.90 | PDE4D (0.41) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL917329 | 0.90 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL916681 | 0.89 | PIK3CD (0.39) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | ADRB2, ADRB1, ADRA2C | PDE4D 45/4885PDE4A 17/4885PDE4B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.